[Efficacy of detection of specific nuclear protein of matrix 22 in the urine in diagnosis of urinary bladder cancer].
The method is based on enzyme immunoassay for definition of nuclear matrix proteins forming part of the cell nuclear capsule. Quantity of these proteins increase 20-80 times in cancer of the bladder. A total of 83 patients participated in the trial. Group 1 consisted of 18 patients with primary bladder cancer, group 2 - of 26 patients with histologically confirmed bladder cancer recurrence. Group 3 - 19 patients with operated bladder cancer without recurrent disease for at least 6 months. Control group - 20 healthy donors. The test urine sample was placed into a test hole and 30 min later the result was assessed. Overall sensitivity of the method was 52% (p < 0.05). Sensitivity of the test increases with progression of the disease: T1 - 37%, T2 - 75%, T3 - 80% (p < 0.05); G1 - 30%, G2 - 50%, G3 87% (p < 0.05). Overall specificity was 95% (p < 0.05). Thus, nuclear matrix proteins 22 represent a prospective marker of the bladder cancer with high specificity and sensitivity in defining not only primary tumors but also the disease recurrences.
Darenkov
S P
SP
Perlin
D V
DV
Chernyshev
I V
IV
Parshina
V N
VN
Ivanov
A V
AV
Iarovoĭ
S K
SK
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000652:urine*; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques / Q000379:methods*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis*; D009687:Nuclear Proteins / Q000652:urine*; D011379:Prognosis; D012680:Sensitivity and Specificity; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis*
D014408:Biomarkers, Tumor; D009687:Nuclear Proteins; C100379:nuclear matrix protein 22